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Abstract
Background: Recent published studies on efficacy and safety of antimalarial treatment in children with Severe 
Acute Malnutrition (SAM) suffering from uncomplicated malaria are not available. 
Methods: Between March 2007 and December 2010 the efficacy of AS+AQ in treating uncomplicated malaria 
children under five with SAM was carried out in Lwiro (Eastern Republic Democratic of Congo) according to the WHO 
standard protocol. Among the 445 children included, 69 had SAM. AS+AQ was given according to national protocol. 
Analysis was done using per protocol method. Odds ratio (OR) and their 95% confidence interval (95% CI) were 
computed.
Results: The treatment failure rate was 24.4% of 414 infections included in the analysis. After adjustment for 
malaria parasitemia, ACPR in children without SAM were 73.0% when it was 91.4% among those with SAM (OR 
3.15 95%CI 1.19 – 8.30). Malaria parasitemia median at admission was statistically low among children who had 
subsequently Adequate Clinical and Parasitological Response (ACPR). 
Conclusion: AS+AQ has a good efficacy among children with both uncomplicated falciparum malaria and 
malnutrition including severe acute form. AS+AQ dosing national strategy unmodified can be used, to treat under five 
children with malnutrition including severe acute form suffering from uncomplicated malaria. 
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Introduction 
In Sub-Saharian African, malaria and malnutrition often 
co-exist and represent an important public health burden [1,2]. 
Prompt treatment with an effective antimalarial treatment is one 
of the cornerstones of malaria control [3]. Because of unacceptable 
resistance, chloroquine (CQ), The most affordable and widely available 
antimalarial treatment in the past, has been replaced, according to the 
World Health Organization recommendations, by artemisinin-based 
combination treatments (ACT) [4,5]. This was followed by a strong 
advocating of the use of the ACT [6]. 
In Eastern Democratic Republic of Congo (DRC), resistance of 
Plasmodium falciparum to CQ has been documented since 1983 and 
was estimated at 80% in 2001 [7]. This prompted the National Malaria 
Control Program (NMCP) to change in 2005 the national antimalarial 
treatment policy and the first line treatment, from CQ to amodiaquine 
plus artesunate (AS+AQ). Nevertheless, since its implementation, few 
studies on AS+AQ efficacy have been carried out [8-10], and none of 
them took into account the patients’ nutritional state. Nevertheless 
it has been often reported that both malnutrition and malaria affect 
antimalarial disposition [11,12]. 
Malaria is endemic in areas where malnutrition is common. 
Among children suffering from uncomplicated malaria to treat 
using antimalarial for which efficacy tests are achieved, a good many 
of them are malnourished. Yet severely malnourished children are 
usually excluded from antimalarial efficacy studies. Consequently, to 
our knowledge, there are no recent published studies on efficacy and 
safety of antimalarial treatment in severely malnourished children 
with uncomplicated malaria. Therefore there is a need to further 
study the efficacy and the safety of artemisinin-based combination for 
uncomplicated malaria treatment in malnourished children although 
its efficacy and safety have been reported for use in children in Africa. 
We compared the efficacy and safety of AS+AQ dosing DRC 
national strategy in malnourished vs non malnourished children aged 
6–59 months with uncomplicated clinical falciparum malaria. 
Methodology
The study was carried out between March 2007 and December 
2010 in Lwiro pediatric hospital (LPH), in South Kivu province, 
Katana health district, at the eastern border of DRC. LPH is a unit of 
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Sciences Naturelles”), the oldest research center in the Kivu region for 
the last 60 years. 
Patient recruitment 
Children with suspected uncomplicated malaria attending LPH or 
its satellite nearest health centre were screened and enrolled in the study 
if they met the following inclusion criteria: age 6 -59 months old, fever 
(axillary temperature ≥37.5°C) or a history of fever in the previous 24 
hours, Plasmodium falciparum mono-infection with density between 
1,000 and 200,000/μl. Exclusion criteria were the following: cause for 
fever other than malaria; dangers signs (unable to sit or stand up, unable 
to drink or breastfeed, lethargy or unconsciousness, recent history of 
convulsions, persistent vomiting) or signs of severe malaria [13]. 
The aim and the procedures of the study were explained to the 
parent/guardian and an individual informed consent was obtained. 
Treatment 
Enrolled children were treated with AS+AQ (Falcimon®, Cipla 
ltd, Mumbai Central, Mumbai 400008, India) at the dose of 4 mg/kg 
for AS and 10 mg/kg for AQ given over 3 days (dosing DRC national 
strategy). AS+AQ was procured by Asrames (“Association régionale 
d’Aprovisionnement en Médicaments Essentiels”), the drug’s regional 
central distribution located in Goma, North Kivu province. Treatment 
was administered over 3 days (day 0-2) under the supervision of a nurse 
who kept the children at the clinic for about 1 hour post-treatment 
to check for possible vomiting. Treatment failures were given a full 
course of quinine according to the NMCP guidelines. Children with 
severe acute malnutrition were included in a nutritional rehabilitation 
program and managed according to the national nutritional therapeutic 
protocol. 
Follow-up
After completion of the treatment, scheduled visits were at days 3, 
7, 14 and 28. Between visits parents were encouraged to attend LPH 
whenever their child was sick. Community health workers did regular 
home visits to remind parents/guardians the next scheduled meeting.
Laboratory tests 
Each visit a blood sample was collected by finger prick for thick 
and thin smears that were stained, with 3% Giemsa for 30 min (thin 
smears were first fixed with methanol). Parasite density was estimated 
by counting the number of asexual parasites against 200 White Blood 
Cells (WBC), assuming a WBC count of 8000/ µL. Serum albumin was 
measured using the bromocresol green assay on spectrophometer.
Anthropometric and clinical measurements
Weight, height and the middle upper arm circumference (MUAC) 
were collected at each follow-up visit by a skilled nurse from the 
HPL according to international recommendations [14]. Axillary 
temperature was measured with a digital thermometer.
Outcome measure 
Outcomes were assessed after 28 days and were classified into 
four categories of therapeutic responses, i.e. Early Treatment Failure 
(ETF), Late Clinical Failure (LCF), Late Parasitological Failure (LPF), 
Adequate Clinical and Parasitological Response (ACPR) [13]. 
Statistical analysis 
Children were not included in the analysis if (1) the parents/
guardians had administered another antimalarial during follow – up; 
(2) they withdrew consent; (3) the child had a concomitant disease that 
would interfere with the treatment outcome; (4) children were lost to 
follow up after two successive missing visits. 
The z scores (ZS) height for age (HAZ), weight for age (WAZ) 
and weight for height (WHZ) were computed with the software WHO 
Anthro V2.0.4 using the reference population as defined by WHO in 
2006 [15]. 
The HAZ, WHZ, WAZ, MUAC, albumin and the presence of 
edemas were used to quantify the degree of under nutrition. The cut 
offs were 115 and 125 mm for the MUAC and -3 and -2 for HAZ, WHZ 
and WAZ ([16,17]). Acute malnutrition was defined as a WHZ ≤ -2 
while chronic malnutrition as a ZS for HAZ ≤ -2 [16]. Severe acute 
malnutrition (SAM) was defined by a WHZ < -3 and/or the presence 
of nutritional edema [17]. According to the previous experience on the 
prognostic indices for mortality in LPH, thresholds for albumin were 
16 and 23 mg/L. 
Analysis of treatment outcome was per protocol. Either the χ² or 
the Fisher exact tests were used for proportions comparison, Mantel—
Haenszel for adjustment and non parametric Kruskal-Wallis test for 
continuous variables with skewed distribution. Odds ratio (OR) for 
failure was computed with 95% confidence intervals (95%CI). All 
reported p-values were two-sided, considered statistically significant if 
less than 0.05.
Ethical considerations
The protocol was submitted to and approved by the Lwiro CRSN 
ethical committee. The procedure for obtaining consent was according 
to international guidelines and local habits for research on human 
subjects. Parents/guardians were informed they could withdraw at any 
time without compromising access to health care. 
Results 
The figure 1 gives the trial profile. Baseline characteristics are 
reported in Table 1. The median age was 26.5 months (range: 6.0 – 
57.97). SAM was found in 14.4% (62/431) children. Median age was 
30.2 months (range: 7.3 – 56.9) in children with SAM vs 25.5 months 
(range: 6.0 – 57.97) in those without SAM (p=0.005). The risk for SAM 
increased with age, i.e. compared to <12 months old, odds ratio (OR): 
1.66 (95% CI: 0.55 -5.01) in 12-23 months old, 3.59 (95%CI: 1.30 – 
9.96) in 24 – 35 months old and 3.16 (1.14 – 8.74) in 36 – 59 months 
old. Nutritional status did not differ by gender. 
Median parasite density was 26,600/μl (range: 1,000 – 198,000) and 
significantly lower in older children (Table 2) and in the undernourished 
one (Table 2). The body temperature was significantly lower in children 
suffering from SAM (n=62) [mean (standard deviation) 37.0°C (0.9)] 
compared to those without SAM (n=369) [mean (standard deviation) 
38.3°C (1.3)] (p < 0.001).
Overall, by day 28, the ACPR was 75.6% (313/414) and the total 
treatment failure was significantly lower in malnourished children after 
adjustment for malaria parasitemia (Table 3). Median parasitemia at 
admission was significant lower in children whose outcome was ACPR 
(21, 560/µL; range: 1,000 – 198,000) than in those with LCF (46,920/µL; 
range: 1,120 – 193,600) (n=69) and LPF (41,560/µL (2,020 – 140,000) 
(n=32) (p < 0.001). 
No child developed severe malaria after enrolment. One child with 
severe acute malnutrition died at day 2. 
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The Table 4 summarizes the adverse events (AEs) by nutritional 
status. Nutritional status did not have any effect on the occurrence of 
AEs. At least one adverse event concomitant with drug administration 
occurred in 9.7% (6/62) children with SAM as compared to 6.5% 
(24/369) without SAM (p=0.52). There were two severe adverse events 
among SAM children, both of them asthenia as the parent/guardian 
reported that the child could not participate to habitual activities. 
Discussion
After adjustment for malaria parasitemaia, more than a quarter of 
children (27.9%) without SAM experienced a treatment failure while 
this proportion was 8.6% among those with SAM. Children with SAM 
or MUAC < 125 mm had ACPR OR > 1 compared to those without 
SAM or with MUAC ≥ 125 mm. This can suggest that AS+AQ has a 
good efficacy among children with both uncomplicated falciparum 
malaria and malnutrition including a severe acute form in spite of their 
multiple deficiencies. 
These results indicate also that the tolerance of AS+AQ dosing 
national strategy was globally good among children including those 
with SAM. 
Overall, these results suggest that AS+AQ dosing national strategy 
unmodified can be used, to treat under five children with malnutrition 
including SAM suffering from uncomplicated falciparum malaria. Even 
if this study had not aimed to monitor AS+AQ efficacy, the total failure 
rates observed could be an alert suggesting that it could be indicated for 
DRC to think about possible actions for its malaria drug policy. 
However, this study has important limitations requiring to be 
mentioned. 
First, the study took place when malaria were hypoendemic all over 
Katana district. A large program of insecticide-treated bed nets (ITNs) 
distribution began when the study was carried out. A former study 
conducted in 1983 in the same region had shown plasmodia index 
variation between 25 and 44 percent indicating a mesoendemic malaria 
level [18]. When recruiting, it was difficult to include children suffering 
from malnutrition and uncomplicated malaria with parasitemia ≥ 
1000 trophozoites/µL, one of major criteria inclusion in the study. The 
decrease of malaria endemicity during the study time add to the difficult 
to get malnourished children meeting inclusion criteria led to extend 
the recruitment period. During this period, Plasmodium species could 
change their sensitivity pattern to anti-malarial drugs. 
Secondary, in this study we did not measure AS+AQ blood levels 
to demonstrate drug and metabolite concentration or its disposition 
in malnourished children. This may have led either to overestimations 
or to underestimation of total failure rates. Nevertheless, most of 
anti-malarial efficacy studies don’t include confirmation of drug 
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Figure 1: Trial profile.
% (number) fever % (number)
Age (in months)
< 12 16.2 (70) 72.9 (51)
12 - < 24 26.9 (116) 55.2 (64)
24 - < 36 26.0 (112) 71.4 (80)
36 - 59 30.9 (133) 57.1 (76)
Gender
Female 48.7 (210) 63.8 (134)
Edema
Yes 13.0 (56) 25.0 (14)
WHZ
< -3 3.9 (17) 17.6 (3)
-3 - < -2 7.0 (30) 43.3 (13)
>= -2 89.1 (384) 66.4 (255)
HAZ
< -3 42.5 (183) 50.3 (92)
-3 - < -2 27.1 (117) 70.9 (83)
>= -2 30.4 (131) 73.3 (96)
MUAC (in mm)
< 115 7.4 (32) 31.3 (10)
115 - < 125 10.4 (45) 53.3 (24)
>= 125 82.1 (354) 66.9 (237)
Serum albumin (g/L)
< 16 2.8* (12) 8.3 (1)
16 - < 23 6.5* (28) 35.7 (10)
>= 23 90.7* (390) 66.7 (260)
* n=430
Table 1: Baseline characteristics under five children with uncomplicated 
falciparum malaria treated with AS+AQ in eastern DRC, from march 2007 to 
December 2010. (n=431). 
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metabolism; demonstration of the persistence of parasites in a patient 
receiving directly observed therapy is quite often considered sufficient. 
Thirdly, in this study neither PCR (polymerase chain reaction) for 
confirmation of failure has been performed. This may also have led 
overestimations of failure instead of the re – infection. But the study 
has been carried out while a larger program of ITNs took place in the 
region. This could suggest that re-infection level could be low. 
Lastly, these results may not be representative of the whole country. 
DRC is a huge country with multifaceted environmental factors 
including nutritional and malaria transmission patterns which may 
lead to regional variability in anti-malarial efficacy treatments. 
In spite of these above limitations, this study has a public health 
strategy goal as a tool for uncomplicated malaria treatment in 
malnourished under five children using AS+AQ DRC national dosing. 
Anti-malarial efficacy studies are scares in DRC although malaria is 
endemic in this huge country. More, there is no study which evaluated 
in the past anti-malaria efficacy in malnourished children in spite of 
malnutrition prevalence.
Since 2000, ACT has been recommended by WHO for the treatment 
of uncomplicated malaria [5]. By this way ACT has been adopted as a 
first-line treatment for uncomplicated malaria in several sub-Saharan 
countries among them the DRC. Unfortunately there are very limited 
pharmacokinetic studies of artemisinin, the main drug recommended 
for combination and derivate in African children in which chronically 
malnutrition is prevalent; therefore the relationship between plasma 
drug concentration and efficacy in these patients is unknown [19]. 
However, in a recent study, Verret and al. [12] concluded to an 
efficacy of artemisinin-based combination therapies in chronically 
n Median per µL (range) p
Age (in months) 0,033
< 12 70 39 100 (1600 - 163420)
12 - < 24 116 24 570 (1200 - 193600)
24 - < 36 111 26 800 (1120 - 198000)
36 - 59 133 19 280 (1000 - 170820)
Gender 0,76
Female 210 26 480 (1000 - 181000)
Male 220 26 900 (1040 - 198000)
SAM < 0,001
Yes 61 7 600 (1040 - 162280)
No 369 31 000 (1000 - 198000)
MUAC (mm) 0,008
< 115 32 10 550 (1460 - 110660)
115 - < 125 45 19 840 (1120 - 198000)
≥ 125 353 29 880 (1000 - 193600)
Albumin (g/dL) < 0,001
< 16 12 2 330 (1040 - 32240)
16 - < 23 28 10 040 (1680 - 88660)
≥ 23 390 29 940 (1000 - 198000)
HAZ 0,016
< -2 299 24 390 (1000 - 198000)
≥ -2 131 34 120 (1040 - 181000)
Table 2: Malaria parasitemia by several features among under five children with 
uncomplicated falciparum malaria treated with AS+AQ in eastern DRC, from 
march 2007 to December 2010. 
malnourished children for repeated episodes of malaria in Ugandan 
children. 
Looking at the way of malaria prevention in malnourished 
children, Danquah et al. [20] observed that the protective efficacies of 
intermittent preventive treatment with sulfadoxine-pyrimethamine in 
malnourished children in northern Ghana were roughly half or even 
less of those observed in non-malnourished children. 
Our results by which children without SAM experienced a poor 
response to AS+AQ treatment than SAM children can be consistent 
with those done in studies aiming to identify pre-treatment risk factors 
of uncomplicated malaria treatment failure with CQ [21-23]. In those 
studies younger age, higher baseline temperature and higher initial 
parasitaemia were predictors of malaria treatment failure [21-23]. In 
our study, SAM children were significantly younger, had low body 
temperature and less malaria parasitemia density compared to those 
without SAM. Warsame et al. [24] observed also that patients who 
experienced clinical failure had significantly higher initial parasitaemia 
than those in whom there was an adequate clinical response.
Independently of the above mentioned factors predicting 
poor response to uncomplicated clinical malaria treatment, it was 
established that physiological changes in children with malnutrition 
were associated with abnormal disposition of drugs which could 
necessitate drug dosage modifications [25]. 
In human, Pussard and al observed that malaria and malnutrition 
increased plasma concentrations of quinine and reduced both the 
volume of distribution and the total plasma clearance [26]. Measuring 
the response to an acute uncomplicated Plasmodium falciparum 
malaria treatment with CQ, Olanrewaju WI and Johnson AW 
[27] observed that the proportion of children with persistence or 
recrudescence of parasitemia on days 4-7 and no significant reduction 
of parasitemia was higher among malnourished children compared to 
children with satisfactory nutritional status.
Because of the lack of sufficient published topical studies, the 
mechanism by which malnutrition can enhance or decrease anti-
malarial efficacy is unknown. 
In a former study in an animal model, vitamin E deficiency 
enhanced the antimalarial action of qinghaosu against Plasmodium 
yoelii in young female mice, both in terms of decreased parasitemia 
and improved survival, but Selenium deficiency did not [28].
Not withstanding malnutrition, our results related to anti-malarial 
efficacy could be consistent with studies carried out after AS+AQ 
implementation in DRC for uncomplicated malaria treatment. In 2004, 
a study conducted in the south of the South Kivu province presented 
a day 28 PCR genotyping-adjusted failure rates of 6.7% using AQ+AS 
[8]. Between 2003 to 2004, in Boende in north-west, the unadjusted 
total failures on day 28 was 41.0%; it was 8.8% in Kabalo in southeastern 
of DRC [29]. These total rates failures were observed before the PNLP 
had introduced AQ + AS as the first-line regimen for uncomplicated 
malaria treatment through the whole country in 2005. More than five 
years later it can be understandable that the total failure rates could 
raise. By using, usually the drug efficacy steadily declined. In Rwanda, 
in the neighborhood of South Kivu province, using the combination 
amodiaquine + sulfadoxine/ pyrimethamine (AQ + SP), the total rates 
failures at day 28 was estimated as 17% in 2003 [24]. Two years after its 
adoption as the first-line antimalarial the total rates failures at day 28 
raised up 25% [30]. 
Citation: Ndeba PM, D’Alessandro U, Hennart P, Donnen P, Porignon D, et al. (2012) Efficacy of Artesunate Plus Amodiaquine for Treatment of 
Uncomplicated Clinical Falciparum Malaria in Severely Malnourished Children Aged 6–59 Months, Democratic Republic of Congo. J Clin 
Exp Pathol S3:005. doi:10.4172/2161-0681.S3-005
Page  5  of 6
J Clin Exp Pathol                                                                                                                          ISSN: 2161-0681 JCEP, an open access journaljournal Epidemiology and Ecology ofParasitic Diseases
Nutritional indicator            % (Number)          % (Number) OR* (95% IC)* p
Severe Acute malnutrition (SAM) Yes (n=58) NO (n=356) 0.002
Late Clinical Failure (LCF) 5.2 (3) 18.5 (66) 0.30 (0.09 – 0.1.01)
Late Parasitological Failure (LPF) 3.4 (2) 8.4 (30) 0.47 (0.11 – 2.08)
Total Failure (TF) 8.6 (5) 27.9 (96) 0.32 (0.12 – 0.84)
Adequate Clinical and Parasitological Response (ACPR) 91.4 (53) 73.0 (260) 3.15 (1.19– 8.30)
MUAC < 125 mm (n=74) ≥ 125 mm (n=340) 0.033
Late Clinical Failure (LCF) 6.8 (5) 18.8 (64) 0.35 (0.13 – 0.91)
Late Parasitological Failure (LPF) 6.8 (5) 7.9 (27) 0.94 (0.35 – 2.55)
Total Failure (TF) 13.5 (10) 26.8 (91) 0.48 (0.23 – 0.98)
Adequate Clinical and Parasitological Response (ACPR) 86.5 (64) 73.2 (249) 2.10 (1.02 – 4.34)
Serum albumin <23 g/L (n=38) ≥ 23 g/L (n=375) 0.22
Late Clinical Failure (LCF) 10.5 (4) 17.3 (65) 0.78 (0.26 – 2.37)
Late Parasitological Failure (LPF) 5.3 (2) 8.0 (30) 0.84 (0.19 – 3.76)
Total Failure (TF) 15.8 (6) 25.3 (95) 0.78 (0.30 – 2.01)
Adequate Clinical and Parasitological Response (ACPR) 84.2 (32) 74.7 (280) 1.29 (0.50 – 3.31)
HAZ < -2 (n=290) >= -2 (n=124) 0.78
Late Clinical Failure (LCF) 17.2 (50) 15.3 (19) 1.25 (0.70 – 2.24)
Late Parasitological Failure (LPF) 7.2 (21) 8.9 (11) 0.85 (0.40 – 1.83)
Total Failure (TF) 24.5 (71) 24.2 (30) 1.11 (0.67 – 1.82)
Adequate Clinical and Parasitological Response (ACPR) 75.5 (219) 75.8 (94) 0.90 (0.55 – 1.49)
*Ajust for malaria parasitemia with 26 600/µL as threshold.
Table 3: Therapeutic responses to  AS+AQ by nutritional indicators status in under five children with uncomplicated falciparum malaria in eastern DRC, between march 
2007 to December 2010.
Lastly, the most common adverse events observed were anorexia, 
vomiting, nausea and diarrhoea. These events observed are consistent 
with those in Rwanda using AS+AQ [31]. Given that drug retention 
explained by the pathophysiological changes occurring in malnutrition 
which could result in adverse events which may be masked by a 
constellation of signs malnutrition, in our study, the drug tolerance 
was globally good among children including those with SAM despite 
their weakness. All children with SAM received were admitted in an 
intensive phase of the nutritional rehabilitation program. This can 
suggest that administration of AS+AQ among children with respecting 
a regular rhythm of the daily diet can decrease the drug adverse events. 
However, this study had not aimed to monitor AS+AQ efficacy, 
although these results cannot be representative for the whole huge 
country, they should alert the DRC national program to monitor 
the efficacy of its first-line anti-malarial for uncomplicated malaria 
treatment according to WHO malaria reports [32]. Actions including 
countrywide as ascertainment of treatment failure, assessment of other 
options available, and their cost and distribution, and reaching final 
consensus on the need to change should be carried out [3].
Conclusion
In Area where malaria and malnutrition co-exist, AS+AQ dosing 
recommended unmodified is an effective and safe drug which can be 
used to treat under five children with malnutrition including severe 
acute form suffering from uncomplicated falciparum malaria. 
But the total failure rates observed in this study are an alert which 
could suggest that it could be indicated for DRC sanitary authorities to 
think about the possible actions of the malaria drug policy, even if this 
study had not aimed to monitor AS+AQ efficacy.
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 Severe acute malnutrition
 Yes (n= 62) No (n= 369)











*The only one predominant adverse events for the same children was considered.
Table 4: Adverse events* by nutritional status among under five children with 
uncomplicated falciparum malaria treated with AS+AQ in eastern DRC, from 
march 2007 to December 2010. 
